BioCentury
ARTICLE | Clinical News

AVI-7288: Phase I data

February 17, 2014 8:00 AM UTC

A double-blind, placebo-controlled, U.S. Phase I trial in 40 healthy volunteers showed that once-daily 1, 4, 8, 12 and 16 mg/kg doses of IV AVI-7288 for 14 days were well tolerated with no serious or ...